Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1109-1115

  Korthals, Mark ^a,b   Sehnke, Nina ^a   Kronenwett, Ralf ^a,c   Schroeder, Thomas ^a   Strapatsas, Tobias ^a   Kobbe, Guido ^a   Haas, Rainer ^a   Fenk, Roland ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Sividon Diagnostics   (Germany)

Author keywords

IgH PCR; Minimal residual disease; Multiple myeloma

Indexed keywords

ALBUMIN; ALPHA INTERFERON; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IDARUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT TOOL; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL STAGING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; REMISSION; RETROSPECTIVE STUDY; SEROLOGY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84879376432     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.025     Document Type: Article

References (32)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. NEngl J Med 1996, 335:91-97.
2. Haas R., Bruns I., Kobbe G., Fenk R. High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Rec Res Cancer Res 2011, 183:207-238.
3. Fenk R., Haas R., Kronenwett R. Molecular monitoring of minimal residual disease in patients with multiple myeloma. Hematology 2004, 9:17-33.
4. Szczepanski T, Orfao A, van der Velden, etal. Minimal residual disease in leukaemia patients. Lancet Oncol 2001 Jul;2:409-417.
5. Harousseau J.L., Attal M., Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114:3139-3146.
6. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med 2005, 352:2487-2498.
7. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. NEngl J Med 2007, 357:2123-2132.
8. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. NEngl J Med 2007, 357:2133-2142.
9. Hart A.J., Jagasia M.H., Kim A.S., et al. Minimal residual disease in myeloma: Are we there yet?. Biol Blood Marrow Transplant 2012, 18:1790-1799.
10. Bruggemann M., Schrauder A., Raff T., et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
11. Neumann F., Markett J., Fenk R., et al. Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study. Hematol Oncol 2008, 26:213-218.
12. Paiva B., Vidriales M.B., Cervero J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
13. Paiva B., Gutierrez N.C., Rosinol L., et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012, 119:687-691.
14. Sarasquete M.E., Garcia-Sanz R., Gonzalez D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
15. Bakkus M.H., Bouko Y., Samson D., et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004, 126:665-674.
16. Korthals M., Sehnke N., Kronenwett R., et al. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 2012, 18:423-431.
17. Putkonen M., Kairisto V., Juvonen V., et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010, 85:416-423.
18. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
19. Billadeau D., Prosper F., Verfaillie C., et al. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia 1997, 11:1565-1570.
20. Cremer F.W., Ehrbrecht E., Kiel K., et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 2000, 26:851-858.
21. Kiel K., Cremer F.W., Rottenburger C., et al. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 23:1019-1027.
22. Lipinski E., Cremer F.W., Ho A.D., et al. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 28:957-962.
23. Raab M.S., Cremer F.W., Breitkreutz I.N., et al. Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Ann Oncol 2005, 16:611-617.
24. Blade J., San Miguel J.F., Fontanillas M., et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. JClin Oncol 1996, 14:2167-2173.
25. Fenk R., Ak M., Kobbe G., et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 2004, 89:557-566.
26. van der Velden V.H., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
27. Nowakowski G.S., Witzig T.E., Dingli D., et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005, 106:2276-2279.
28. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: A simple risk stratification system. Blood 2006, 107:3384-3388.
29. Liu H., Yuan C., Heinerich J., et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. Leuk Lymph 2008, 49:306-314.
30. Cooke F., Bakkus M., Thielemans K., et al. Use of quantitative ASO-PCR to predict relapse in multiple myeloma. Br J Haematol 1999, 105:317-319.
31. Rasmussen T., Hansson L., Osterborg A., et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003, 101:4607-4610.
32. Durie B.G., Salmon S.E. Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. Annu Rev Med 1975, 26:283-288.